Dealing with robot-assisted surgery for rectal cancer: Current status and perspectives

Table 6 Short-term and long-term oncologic outcomes of robotic TME for rectal cancer

Ref.	LN yield	CRM+ n (%)	DRM+ n (%)	FU (mo)	LR (%)	DR (%)	DFS (3 yr), (%)	OS (3 yr), (%)
Hellan et al[16]	13 (7-28)1	0	0	132	0	10.3	-	-
Baik et al[17]	17.5 (4-43)1	4 (7.1)	0	14.32	0	3.6	-	-
Choi et al[18]	20.6 (6-48)3	1 (2)	0	-			-	-
Baek et al[19]	14.5 (3-28)1	0	0	20.24	3.1	9.4	73.7	96.2
Pigazzi et al[15] (Multicenter study)	14.1 (1-39)3	1 (0.7)	1 (0.9)	17.44	1.5	9.0	77.6	97
Baik et al[20]	15.6 ± 9.0 (1-49)+	21 (5.7)		26.54	3.6	17.6	79.2	93.1
Ieo series, Ghezzi et al[14]	14.5 (2-45)3	5 (4.9)	2 (1.9)	30.02	4.0	10.7	79.2	92

¹mean ± SD (range);

²median followe-up;

³mean lymphnode yield;

⁴mean followup. LN: Lymph node; CRM+: Circumferential resection margin positivity; DRM+: Distal resection margin positivity; FU: Follow up; LR: Local recurrence; DR: Distant recurrence; DFS: Disease free survival; OS: Overall survival.